Conference call today at 4:30 p.m. EDT My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about XNCR MONROVIA, Calif., May 14, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the first quarter ended March 31, 2014 and provided a review of recent business highlights. "We have continued to advance our drug development programs and we plan to have preliminary data from both of our lead programs, XmAb7195 and...
↧
